Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
AstraZeneca Nordic Baltic, Södertälje, Sweden.
Clin Epidemiol. 2015 Feb 26;7:213-23. doi: 10.2147/CLEP.S78145. eCollection 2015.
To examine the annual rate and cumulative prevalence of statin use in Denmark 2004-10, including adherence of use and attainment of cholesterol targets.
We included all individuals aged 18-86 years with a first statin prescription in Northern Denmark in 2004-10. We calculated the annual rate and cumulative prevalence of statin use. We examined cholesterol values before and after start of statins and the proportion reaching targets according to European guidelines and cardiovascular risk group.
The study population consisted of 161,646 new statin users (51% men; median age 62 years). The peak rate of new statin initiators occurred in 2008, and a cumulative prevalence of 94 users per 1,000 population was reached in 2010. In total, 98% of new users started with simvastatin. Eighty-eight percent (142,897) did not switch statin type during follow-up. Overall persistence was 84%. The reduction in median total cholesterol in new statin users was 28% (from 6.3 mmol/L to 4.5 mmol/L), while it was 43% (from 4.0 mmol/L to 2.3 mmol/L) for low-density lipoprotein cholesterol. Among patients with very high cardiovascular risk, 66% attained the recommended total cholesterol target; corresponding figures were 74% among high-risk patients and 80% among low- to moderate-risk patients. Corresponding figures for low-density lipoprotein cholesterol were 54%, 82%, and 88%, respectively.
Statin use has become very prevalent in Danish adults, with high adherence. Cholesterol reduction after statin initiation is similar to that found in clinical trials, yet a substantial proportion of patients does not reach target cholesterol levels.
研究 2004-2010 年丹麦他汀类药物的年使用率和累计流行率,包括使用的依从性和胆固醇目标的达标情况。
我们纳入了 2004-2010 年在丹麦北部首次开具他汀类药物处方的所有 18-86 岁人群。我们计算了他汀类药物的年使用率和累计流行率。我们检测了开始使用他汀类药物前后的胆固醇值,以及根据欧洲指南和心血管风险组达到目标的比例。
研究人群包括 161646 名新的他汀类药物使用者(51%为男性;中位年龄 62 岁)。新开始使用他汀类药物的高峰出现在 2008 年,到 2010 年达到每 1000 人中有 94 人使用的累计流行率。新使用者中,98%的人开始使用辛伐他汀。88%(142897 人)在随访期间未更换他汀类药物类型。总体持久性为 84%。新他汀类药物使用者的中位总胆固醇降低了 28%(从 6.3mmol/L 降至 4.5mmol/L),而低密度脂蛋白胆固醇降低了 43%(从 4.0mmol/L 降至 2.3mmol/L)。在极高心血管风险患者中,66%达到了推荐的总胆固醇目标;高危患者的相应比例为 74%,低至中度风险患者的相应比例为 80%。低密度脂蛋白胆固醇的相应比例分别为 54%、82%和 88%。
他汀类药物在丹麦成年人中的使用已非常普遍,且具有较高的依从性。他汀类药物治疗后胆固醇的降低与临床试验相似,但仍有相当一部分患者未达到胆固醇目标水平。